1. Introduction {#sec1}
===============

Hydrocortisone is a naturally occurring corticosteroid hormone secreted by the adrenal cortex and released during times of stress. The synthetic drug is employed in the management of inflammatory and rheumatoid diseases, allergic conditions, and autoimmune disorders such as Addison\'s disease (adrenal insufficiency disease). Hydrocortisone is commercially available in pharmaceutical formulations such as tablets, capsules, creams, ointments, and injections. Hydrocortisone may exist commercially as the unchanged hormone or as the acetate, cypionate, sodium phosphate, butyrate, valerate, and the sodium succinate forms \[[@B1]\].

A search of the literature revealed that few analytical methods such as ultraviolet spectrophotometry \[[@B2]\], electrokinetic capillary chromatography \[[@B3], [@B4]\], photochemically enhanced fluorescence \[[@B5]\], thin-layer chromatography- (TLC-) densitometry \[[@B1], [@B6]\], and high-performance thin-layer chromatography (HPTLC) \[[@B7]\] have been used for the estimation of hydrocortisone in pharmaceutical formulations. However, modern chromatographic techniques such as high-performance liquid chromatography (HPLC) \[[@B8]--[@B12]\] and ultra-performance liquid chromatography (UPLC) \[[@B13]\] are preferentially employed for the determination of hydrocortisone in conventional pharmaceutical products such as tablets, creams, and injections. The different HPLC methods employ different chromatographic conditions including the use of complex and sometimes expensive solvent systems. Thus, access to some of these solvent systems in resource-poor countries in the developing countries can be challenging. The development of a simple and economical HPLC method using readily available reagents for the identification and quantification of hydrocortisone in pharmaceutical preparations would be an advantage in resource-poor countries.

The upsurge of autoimmune diseases such as adrenal insufficiency is a major health concern and the long-term use of conventional hydrocortisone tablets in the management of such a condition is problematic. The twice or thrice daily dosing of conventional hydrocortisone tablets to patients with adrenal insufficiency disease is incapable of mimicking the unique diurnal cortisol circadian pattern. Thus, most persons with adrenal insufficiency continue to suffer from poor therapeutic management resulting in poor quality of life and increased mortality. There is therefore the need for the development of creative and innovative treatment models for hydrocortisone replacement therapy in such dire situations. The use of controlled-release hydrocortisone oral dosage forms holds great promise with the capability to replicate the unique physiological pattern of hydrocortisone. In addition, such formulations are better able to manage and control the levels of morning androgen levels. The accurate monitoring of the quality of these promising new drug therapies is an important prerequisite to obtain quality healthcare \[[@B14]\]. The improved therapy will enhance patient compliance and ensure the delivery of controlled amounts of hydrocortisone at the absorption site compared to the immediate release pattern of conventional tablets \[[@B15]\].

The aim of this study was to develop and validate a simple, sensitive, and reproducible isocratic reverse phase HPLC method with ultraviolet/visible (UV) detection capable of determination and quantification of hydrocortisone in conventional and controlled-release pharmaceutical preparations. The application of the method in determining the content of hydrocortisone in controlled-release and commercially available conventional dosage forms was also studied.

2. Materials and Methods {#sec2}
========================

2.1. Standards and Reagents {#sec2.1}
---------------------------

The reference material of hydrocortisone (Sigma Aldrich, USA), HPLC grade methanol (Fisher Scientific, UK), glacial acetic acid (Fluka, Germany), and water (double distilled) were used. All stock and working solutions were freshly prepared with distilled water for HPLC analyses.

2.2. Hydrocortisone Pharmaceutical Preparations {#sec2.2}
-----------------------------------------------

Fifteen commercially available hydrocortisone pharmaceutical preparations, comprising nine tablet and six injectable formulations, were sampled from retail pharmacies within the Kumasi and Accra Metropolitan areas of Ghana. Additionally, four controlled-release hydrocortisone tablet formulations, two controlled-release capsule formulations, and one conventional release hydrocortisone tablet formulation were obtained from the Department of Pharmaceutics and Microbiology, University of Ghana School of Pharmacy, Accra, Ghana.

2.3. Instrumentation and Optimized Chromatographic Conditions {#sec2.3}
-------------------------------------------------------------

A chromatograph comprising a P100 Spectra Series pump with a 785A Programmable Perkin Elmer UV/VIS absorbance detector was employed in the study. Isocratic mode of elution was employed. Chromatographic separation was successfully achieved on a JT Baker® ODS C18 column (150 × 4.60 mm ID, 5 *μ*m particle size). Ultraviolet detection at a wavelength of 254 nm was able to ensure good resolution of peaks. The injection volume was 20 *μ*L and all analyses were undertaken at ambient temperature. A mobile phase consisting of methanol/water/acetic acid (60 : 30 : 10; v/v/v) at a flow rate of 1.00 ml/min was employed. All chromatographic data were acquired using PowerChrom series 280 integrator software.

2.4. Preparation of Standard Solution {#sec2.4}
-------------------------------------

Fifty milligrams of hydrocortisone reference standard was accurately weighed and dissolved in 25 ml of methanol as the diluent. The solution was transferred into a 50 ml dry volumetric flask and was then sonicated for 5 min. The volume was made up to the mark with methanol and mixed thoroughly (1 mg/ml stock solution). A one in ten (1 in 10) dilution was made to obtain a working solution with concentration of 0.10 mg/ml of hydrocortisone. This solution with the required working concentration was then injected to determine the retention time of the analyte of interest using the developed method.

2.5. Analytical Method Validation {#sec2.5}
---------------------------------

The new HPLC method was validated in terms of linearity, limits of detection and quantification, accuracy, precision (intraday and interday), specificity, robustness, and stability, in compliance with International Conference on Harmonization (ICH) guidelines \[[@B16]\].

### 2.5.1. Linearity {#sec2.5.1}

Serial dilutions were prepared from the stock solution of hydrocortisone reference standard (1 mg/ml) by pipetting 8.0 ml, 4.0 ml, 2.0 ml, 1.6 ml, 0.8 ml, and 0.4 ml of the stock solution into separate 20 ml volumetric flasks. The solutions were made up to volume with the diluent and mixed thoroughly. Solutions prepared were injected and analyzed using the developed method. The linearity of detector response was established by plotting a graph of concentration versus peak area of hydrocortisone standard and determining the correlation coefficient.

### 2.5.2. Limits of Detection and Quantification {#sec2.5.2}

The limit of detection (LOD) and limit of quantification (LOQ) of the new HPLC method were determined from the linear regression curve obtained from the linearity of hydrocortisone. The slope and standard deviations of the responses of the linear curve were used. The formulae for the calculation of the LOD and LOQ are given below:$$\begin{matrix}
{LOD = \frac{3.3\delta}{S}} \\
 \\
{LOQ = \frac{10\delta}{S},} \\
 \\
\end{matrix}$$where *δ* is standard deviation of the response; *S* is slope of the calibration curve.

### 2.5.3. Accuracy {#sec2.5.3}

Into three separate 10 ml volumetric flasks 1 ml of a 1 mg/ml standard solution of hydrocortisone was pipetted. 0.8 ml, 1.0 ml, and 1.2 ml of formulated hydrocortisone solution (0.1 mg/ml) were added to the three volumetric flasks, respectively, to obtain concentrations at 80%, 100%, and 120% levels. The solutions were analyzed using the developed method. Triplicate determinations were made for each solution and mean percentage recovery calculated.

### 2.5.4. Precision {#sec2.5.4}

Both intraday and interday precision of the HPLC method were assessed. For intraday precision, three solutions of different concentrations were prepared in separate 20 ml volumetric flasks from the stock solution of hydrocortisone reference standard (1 mg/ml) by pipetting 8.0 ml, 2.0 ml, and 0.4 ml of the stock solution. Solutions were made up to volume with methanol. The various solutions where analyzed thrice during a particular day to obtain chromatograms from which recoveries and relative standard deviations (RSD) were calculated. For interday precision, a one in ten (1 in 10) dilution of the stock standard solution was prepared on three different occasions and analyzed. The solutions were analyzed on three consecutive days using the developed HPLC method to obtain chromatograms and the hydrocortisone content and relative standard deviation (RSD) were determined.

### 2.5.5. Specificity {#sec2.5.5}

The developed HPLC method was investigated for specificity to ensure there was no or minimal interference of analyte of interest from the solvent system. The mobile phase (blank) was analyzed, followed by an injection of a sample solution of hydrocortisone. After a ten-minute wash period, the blank was analyzed again.

### 2.5.6. Robustness {#sec2.5.6}

The robustness of the method was examined by introducing small changes in the composition of the mobile phase. Variation by ±10% was done with respect to the methanol component of the mobile phase while keeping the composition of the others constant. Chromatograms obtained were analyzed using the RSD of the responses obtained.

### 2.5.7. Stability {#sec2.5.7}

The stability of solutions of hydrocortisone were studied over a period of 8 hours. Triplicate injections were made each hour and the chromatograms recorded.

2.6. Assay of Hydrocortisone Preparations {#sec2.6}
-----------------------------------------

An amount of finely powdered hydrocortisone powder from each of the nine commercial conventional tablet formulations equivalent to 2.5 mg hydrocortisone was individually weighed accurately and transferred to a 25 ml volumetric flask containing 10 ml of methanol. The solution was sonicated for 5 min and made up to volume with methanol. The resulting solution was then filtered using Whatman filter paper number 41. The filtrate obtained was analyzed by making triplicate injections. The controlled-release hydrocortisone tablet and capsule formulations were analyzed in a similar way. In the analysis of the hydrocortisone injections, aliquots equivalent to 2.5 mg hydrocortisone were pipetted from the six (6) injectable preparations into 25 ml volumetric flasks and treated similarly to above. The peak areas of sample were determined and the amount of hydrocortisone was estimated from the linear regression calibration curves using the developed method. The official United States Pharmacopoeia method \[[@B11]\] was employed in analyzing the commercial samples. Statistical comparison between the official and developed methods was done using Student\'s *t*-test.

3. Results and Discussion {#sec3}
=========================

Controlled-release hydrocortisone preparations remain formulations of choice in the therapeutic management of adrenal insufficiency disease. This disease condition is a potentially life-threatening autoimmune disorder that requires prompt diagnosis and management to avoid fatality. The use of controlled-release formulations results in more stable cortisol concentrations during the diurnal cortisol circadian pattern than conventional hydrocortisone products \[[@B17]\]. It is however essential that suitable and accurate analytical methods are made available to assess the quality of the products with regard to their content. The development and validation of a simple isocratic RP-HPLC method for the determination of hydrocortisone in both conventional and controlled-release pharmaceutical formulations were the focus of this study. Review of literature indicates the employment of normal phase stationary support material \[[@B18], [@B19]\] and reverse phase stationary support material \[[@B20]\] for the development of HPLC method and further analyses of hydrocortisone products. There is yet no reported reverse phase HPLC with UV detection method capable of analyzing hydrocortisone in both conventional and controlled-release pharmaceutical formulations. The inclusion of acetic acid as a modifier in the mobile phase system ensured efficient resolution of hydrocortisone with minimal matrix effect from both conventional and controlled-release formulations. Readily available and cost effective solvents employed in the mobile phase ensured an efficient resolution and separation of hydrocortisone on a reverse phase column. [Table 1](#tab1){ref-type="table"} presents the optimized chromatographic conditions employed in the determination of hydrocortisone.

3.1. Analytical Method Validation {#sec3.1}
---------------------------------

This method provides an option for the analyses of hydrocortisone in various salt forms compared to the individual methods available in some official compendia such as the United States Pharmacopoeia \[[@B11]\]. The analytical method being reported gave good linear detectable responses in the range of 0.02 to 0.4 mg/ml with coefficient of correlation (*r*^2^) of 0.9989 with well-resolved hydrocortisone and excipient peaks (Figures [1](#fig1){ref-type="fig"}[](#fig2){ref-type="fig"}[](#fig3){ref-type="fig"}--[4](#fig4){ref-type="fig"}). The limit of detection and limit of quantification of 1.0662 × 10^−2 ^mg/ml and 3.23076 × 10^−2 ^mg/ml, respectively, obtained are an indication of the sensitivity of the method. The method showed good accuracy with good recoveries in the range of 98 to 101% recorded at three concentration levels of 80%, 100%, and 120% ([Table 2](#tab2){ref-type="table"}). The method was reproducible with good intraday and interday precision of less than 1% RSD (Tables [3](#tab3){ref-type="table"} and [4](#tab4){ref-type="table"}). The new HPLC method showed high specificity and the robustness was less than 1% RSD (Tables [5](#tab5){ref-type="table"} and [6](#tab6){ref-type="table"}). The method also demonstrated good stability over a period of 8 h (\<6% RSD) ([Table 7](#tab7){ref-type="table"}).

3.2. Application of Developed Method to the Analysis of Commercial Samples {#sec3.2}
--------------------------------------------------------------------------

[Table 8](#tab8){ref-type="table"} presents the characteristics, labelled strength, and assay results of conventional hydrocortisone preparations which were analyzed using both the developed HPLC method and the official USP method. Statistical analysis (*t*-test) of data from the two methods (official/USP and developed) showed no significant difference (*p* \> 0.05) at a 95% confidence interval ([Table 9](#tab9){ref-type="table"}). The analytical method developed provides a relatively cheaper alternative technique for routine postmarket analyses of hydrocortisone formulations in resource-poor countries such as Ghana. The validated method was also successfully applied to the analysis of six controlled-release hydrocortisone tablet and capsule formulations ([Table 10](#tab10){ref-type="table"}). The application of the method in the analyses of tablets (conventional and controlled-release) and parenteral formulations indicated the versatility of the analytical procedure. The analyses of the hydrocortisone formulations yielded percentage hydrocortisone content of 95--104%, 96--103%, and 87--103% for the four controlled-release tablet formulations, two controlled-release capsule formulations, and fifteen conventional hydrocortisone formulations, respectively. All the controlled-release products were of good quality in terms of their content (percentage of content ≥ 90%). The percentage of content of hydrocortisone powder was 100.44%. Twelve products (all 6 injections, 6 tablets) out of the 15 commercial hydrocortisone products analyzed were determined to contain the right amounts of hydrocortisone as per United States Pharmacopoeia (USP) method and the developed HPLC method \[[@B11]\]. This study did not cover other pharmacopoeia specifications such as disintegration and dissolution tests.

4. Conclusion {#sec4}
=============

It can be concluded that the developed and validated simple, isocratic, sensitive RP-HPLC method is useful for the determination and quantification of hydrocortisone in conventional and controlled-release pharmaceutical formulations. The method was successfully applied to commercial samples which indicate the ability of the analytical method to distinguish between good and poor quality hydrocortisone products.
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###### 

Optimized chromatographic conditions for the developed HPLC method.

  Parameters             Optimized conditions
  ---------------------- --------------------------------------------------
  Mobile phase           Methanol/water/acetic acid (60 : 30 : 10, v/v/v)
  HPLC column            JT Baker ODS C18, 5 *µ*m, 4.6 × 150 mm
  Flow rate              1 ml/min
  Wavelength detection   254 nm
  Diluent                Methanol
  Injection volume       20 *µ*L

###### 

Accuracy of the HPLC method showing the mean percentage recovery of hydrocortisone at three concentration levels.

  Concentration levels   Amount taken (mg/ml)   Amount added (mg/ml)   Amount recovered   Percentage recovery (%)
  ---------------------- ---------------------- ---------------------- ------------------ -------------------------
  80%                    0.10                   0.08                   0.07820            97.75
  0.10                   0.08                   0.07840                98.01              
  0.10                   0.08                   0.07836                97.92              
  100%                   0.10                   0.10                   0.10073            100.73
  0.10                   0.10                   0.10120                101.20             
  0.10                   0.10                   0.10052                100.52             
  120%                   0.10                   0.12                   0.11998            99.98
  0.10                   0.12                   0.12062                100.05             
  0.10                   0.12                   0.11934                99.45              

###### 

Intraday precision of proposed HPLC method showing the mean percentage recovery and RSD of hydrocortisone at different concentrations.

  Number of runs   Concentration levels (mg/ml)   Amount recovered^*∗*^ (mg/ml)   Percentage recovery (%)   \% RSD
  ---------------- ------------------------------ ------------------------------- ------------------------- --------
  1                0.02                           0.01990                         99.52                     0.55
  2                0.01997                        99.83                                                     
  3                0.01975                        98.76                                                     
  1                0.10                           0.10052                         100.52                    0.54
  2                0.09945                        99.45                                                     
  3                0.10000                        100.03                                                    
  1                0.40                           0.39952                         99.88                     0.19
  2                0.39828                        99.57                                                     
  3                0.39964                        99.91                                                     

^*∗*^Mean of three replicate determinations.

###### 

Interday precision of proposed HPLC method showing the mean percentage recovery and RSD of hydrocortisone on different days.

  Number of runs   Percentage recovery^*∗*^ (%)           
  ---------------- ------------------------------ ------- --------
  1                100.52                         98.52   100.16
  2                99.45                          99.67   99.51
  3                100.03                         98.36   99.72
  Mean             100.00                         98.85   99.80
  \% RSD           0.54                           0.71    0.33

^*∗*^Mean of three replicate determinations.

###### 

Results of specificity studies of the proposed HPLC method.

  Parameter        Response
  ---------------- ----------------------
  *Mobile phase*   No peak (−)
  Hydrocortisone   Single peak obtained
  *Mobile phase*   No peak (−)

(−): not detected.

###### 

Robustness of proposed HPLC method showing the mean percentage content of hydrocortisone when conditions were varied.

  Sample   Original condition   Varied condition
  -------- -------------------- ------------------
  1        100.52               101.32
  2        100.75               100.65
  3        101.34               99.99
  Mean     100.87               100.65
  \% RSD   0.42                 0.67

###### 

Stability of HPLC method showing the mean recoveries of hydrocortisone in solution over an eight-hour period.

  Time (h)   Mean concentration   \% RSD
  ---------- -------------------- --------
  0          100.72               0.56
  2          100.29               0.63
  4          98.40                1.73
  6          95.82                3.54
  8          93.11                5.79

###### 

Characteristics and labelled strength of commercial hydrocortisone preparations analyzed using the developed HPLC method (DM) and the USP method.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
  Code   Dosage form^*∗*^   Strength   Country of manufacture   Batch number   Date of manufacture   Expiry date   Assay^*∗∗*^ (%) (DM)   Assay^*∗∗*^ (%)\
                                                                                                                                          (USP)
  ------ ------------------ ---------- ------------------------ -------------- --------------------- ------------- ---------------------- ------------------
  HP1    PFI                100 mg     Belgium                  14HB24         04/2014               03/2017       98.41                  98.60

  HP2    PFI                100 mg     China                    131255         12/2013               12/2016       102.60                 102.34

  HP3    PFI                100 mg     Belgium                  14HB52         12/2014               11/2017       100.64                 100.42

  HP4    PFI                100 mg     India                    5AB01007       10/2015               09/2018       101.20                 101.27

  HP5    PFI                100 mg     Belgium                  15HB22         09/2015               08/2018       102.80                 102.83

  HP6    PF1                100 mg     India                    5AE04010       10/2015               09/2018       100.63                 100.35

  HT1    Tablet             10 mg      China                    150801         08/2015               08/2018       86.80                  86.45

  HT2    Tablet             10 mg      France                   5EH3C          05/2015               05/2018       98.90                  98.94

  HT3    Tablet             5 mg       France                   5ET4B          04/2014               04/2017       101.55                 101.72

  HT4    Tablet             10 mg      India                    KC004          02/2014               02/2017       101.27                 101.65

  HT5    Tablet             5 mg       India                    KD157          04/2015               04/2018       87.69                  87.36

  HT6    Tablet             5 mg       India                    KD150          04/2015               04/2018       89.05                  89.03

  HT7    Tablet             10 mg      United Kingdom           13J11/C        10/2013               10/2016       94.38                  94.27

  HT8    Tablet             10 mg      United Kingdom           13J14/B        10/2013               10/2016       100.28                 100.11

  HT9    Tablet             10 mg      United Kingdom           13J12/A        08/2013               08/2016       98.22                  98.09
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

^*∗*^PFI = powder for injection (im/iv). ^*∗∗*^Acceptance criterion = 90--110%.

###### 

Statistical comparison between the developed method and the USP method.

  USP method (column B) versus developed method (column A)   
  ---------------------------------------------------------- ------------------------
  *t*-test                                                    
  *p* value                                                  0.9742
  *p* value summary                                          Ns
  Significantly different? (*p* \< 0.05)                     No
  One- or two-tailed *p* value?                              Two-tailed
  Mean ± SEM of column A                                     97.63 ± 1.415 *N* = 15
  Mean ± SEM of column B                                     97.56 ± 1.440 *N* = 15
  Difference between means                                   −0.06600 ± 2.019
  95% confidence interval                                    −4.202 to 4.070

###### 

Characteristics and labelled strength of pectin-based modified release hydrocortisone preparations analyzed using the developed HPLC method.

  Code   Dosage form   Strength   Assay (%)^*∗*^
  ------ ------------- ---------- ----------------
  HM1    Tablet        100 mg     103.36
  HM2    Capsule       100 mg     95.99
  HM3    Capsule       100 mg     103.29
  HM4    Tablet        100 mg     102.41
  HM5    Tablet        100 mg     104.38
  HM6    Tablet        100 mg     95.34

^*∗*^Acceptance criterion = 90--110 %.
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